2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.099 Stephanie Liu Abstract

PP01.099 Stephanie Liu Abstract

Pdf Summary

Researchers evaluated the pharmacokinetics (PK) of switching from intravenous (IV) dosing to subcutaneous (SC) dosing of atezolizumab, a drug used in the treatment of lung cancer. Atezolizumab is approved for IV dosing at different intervals, and the study aimed to assess PK profiles for patients who switch to SC dosing. The study used a population PK model to simulate PK profiles for patients with metastatic TNBC or resected NSCLC who switched to SC administration after 1, 4, or 6 doses of atezolizumab IV. The minimum concentration during a dosing interval (Ctrough) and the weekly area under the serum concentration-time curve (AUC) were compared between patients who received IV doses only and those who switched to SC dosing. <br /><br />The results showed that patients who switched to SC administration maintained systemic drug exposure, regardless of the cycle at which the switch occurred. The geometric mean Ctrough at steady state (SS) after switching from 1200 mg IV to 1875 mg SC at Cycle 2, 5, or 7 was 249 μg/mL compared to 217 μg/mL for IV dosing only. Similarly, the AUC at SS was 2382 d*μg/mL for the switch group compared to 2285 d*μg/mL for the IV dosing group. <br /><br />In conclusion, the study suggests that patients can safely switch from atezolizumab IV to SC administration while maintaining systemic drug exposure. This finding is important for patients who may prefer the convenience of SC dosing or have issues with IV administration. Further research is needed to validate these findings and assess the clinical implications of switching dosing routes in lung cancer treatment.

Keywords

pharmacokinetics

switching

intravenous dosing

subcutaneous dosing

atezolizumab

lung cancer

PK profiles

minimum concentration

Ctrough

systemic drug exposure